Jian Ma

Dr. Jian Ma


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
JMJian Ma
Jian Ma
SMSmita Matkar
Smita Matkar
XHXin He
Xin He
XHXianxin Hua
Xianxin Hua

6 April 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
JMJian Ma
Jian Ma
BXBowen Xing
Bowen Xing
YCYan Cao
Yan Cao
XHXin He
Xin He
KBKate E Bennett
Kate E Bennett
XHXianxin Hua
Xianxin Hua
Pancreatic beta cells undergo compensatory proliferation in the early phase of type 2 diabetes. While pathways such as FoxM1 are involved in regulating compensatory beta cell proliferation, given the lack of therapeutics effectively targeting beta cell proliferation, other targetable pathways need to be identified. Herein, we show that Pbk, a serine/threonine protein kinase, is essential for high fat diet (HFD)‐induced beta cell proliferation in vivo using a Pbk kinase deficiency knock‐in mouse model. Mechanistically, JunD recruits menin and HDAC3 complex to the Pbk promoter to reduce histone H3 acetylation, leading to epigenetic repression of Pbk expression. Moreover, menin inhibitor (MI) disrupts the menin–JunD interaction and augments Pbk transcription. Importantly, MI administration increases beta cell proliferation, ameliorating hyperglycemia, and impaired glucose tolerance (IGT) in HFD‐induced diabetic mice. Notably, Pbk is required for the MI‐induced beta cell proliferation and improvement of IGT. Together, these results demonstrate the repressive role of the menin/JunD/Pbk axis in regulating HFD‐induced compensatory beta cell proliferation and pharmacologically regulating this axis may serve as a novel strategy for type 2 diabetes therapy.

1 February 2022 in Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
YCYan Cao
Yan Cao
ZFZijie Feng
Zijie Feng
XHXin He
Xin He
XZXuyao Zhang
Xuyao Zhang
BXBowen Xing
Bowen Xing
XHXianxin Hua
Xianxin Hua
Gestational diabetes mellitus (GDM) is a condition of diabetes with onset or first recognition in pregnancy. Its incidence is increasing, and GDM deleteriously affects both mother and the fetus during and even after pregnancy. Previous studies in mice have shown that during pregnancy, β-cell proliferation increases in the middle and late stages of pregnancy and returns to normal levels after delivery. Hormones, such as prolactin, estradiol, and progesterone as well as protein kinases, play important roles in regulating gestation-mediated β-cell proliferation; however, the regulatory relationship between them is uncertain. We previously found that protein kinase Pbk was crucial for basal proliferation of mouse islet cells. Herein we show that Pbk is upregulated during pregnancy in mice and Pbk kinase activity is required for enhanced β- cell proliferation during pregnancy. Notably, knock-in (KI) of a kinase-inactivating Pbk mutation leads to impaired glucose tolerance and reduction of β-cell proliferation and islet mass in mice during pregnancy. Prolactin upregulates the expression of Pbk, but the upregulation is diminished by knockdown of the prolactin receptor and by the inhibitors of JAK and STAT5, which mediate prolactin receptor signaling, in β-cells. Treatment of β-cells with prolactin increases STAT5 binding to the Pbk locus, as well as the recruitment of RNA polymerase II, resulting in increased Pbk transcription. These results demonstrate that Pbk is upregulated during pregnancy, at least partly by prolactin-induced and STAT5-mediated enhancement of gene transcription, and Pbk is essential for pregnancy-induced β-cell proliferation, increase in islet mass, and maintenance of normal blood glucose during pregnancy in preclinical models. These findings provide new insights into the interplay between hormones and protein kinases that ultimately prevent the development of GDM.

21 August 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SDShuyan Dong
Shuyan Dong
MZMing Zhao
Ming Zhao
JZJin Zhu
Jin Zhu
TLTing Li
Ting Li
MYMingze Yan
Mingze Yan
HHHongjiang He
Hongjiang He
The interplay between immune components and the epithelium plays a crucial role in the development and progression of head and neck squamous cell carcinoma (HNSCC). Natural killer (NK) cells, one of the main tumor-killing immune cell populations, have received increasing attention in HNSCC immunotherapy. In this review, we explore the mechanism underlying the interplay between NK cells and HNSCC. A series of immune evasion strategies utilized by cancer cells restrict HNSCC infiltration of NK cells. Overcoming these limitations can fully exploit the antineoplastic potential of NK cells. We also investigated the tumor-killing efficacy of NK cell-based immunotherapies, immunotherapeutic strategies, and new results from clinical trials. Notably, cetuximab, the most essential component of NK cell-based immunotherapy, inhibits the epidermal growth factor receptor (EGFR) signaling pathway and activates the immune system in conjunction with NK cells, inducing innate effector functions and improving patient prognosis. In addition, we compiled information on other areas for the improvement of patient prognosis using anti-EGFR receptor-based monoclonal antibody drugs and the underlying mechanisms and prognoses of new immunotherapeutic strategies for the treatment of HNSCC.

21 May 2026 in SmartMat
Verified
Journal Article
Open access
WWWei Wu
Wei Wu
AAAbid Ali
Abid Ali
LSLi Sun
Li Sun
JHJiahao Hu
Jiahao Hu
LHLina Hameed
Lina Hameed
JMJian Ma
Jian Ma
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy‐chain‐only antibodies (HCAbs). They combine a small size (~12–15 kDa) with high solubility, favorable stability, and antigen‐binding capability. These properties can facilitate recognition of less accessible epitopes, improve tissue penetration in selected settings, and support assay performance under conditions that may challenge conventional antibodies. In recent years, nanobodies have emerged as versatile molecular recognition tools for diagnostic applications and been integrated into diverse detection platforms—including enzyme‐linked immunosorbent assay (ELISA), lateral flow immunoassays (LFIAs), biosensors, and in vivo imaging techniques such as positron emission tomography (PET), single‐photon emission computed tomography (SPECT), and nanobody–quantum dot conjugates. Advances such as multivalent designs, site‐specific conjugation, and optimized expression systems have further enhanced the performance of nanobodies in clinical diagnostics. Here, we summarize recent progress in nanobody‐based diagnostic technologies, outlining the key structural and biochemical features that contribute to their efficacy, reviewing ongoing clinical trials, and highlighting successful technological developments. Additionally, we discuss emerging strategies aimed at creating scalable, sensitive, and application‐ready nanobody‐enabled diagnostic platforms.

30 June 2025 in Rare Metals
Verified
Journal Article
Closed access
PDF file
MLMeng‐Nan Li
Meng‐Nan Li
BCBo Cao
Bo Cao
YWYan‐Ling Wang
Yan‐Ling Wang
HZHang Zhou
Hang Zhou
HYHai‐Xu Yao
Hai‐Xu Yao
FCFeiyun Cui
Feiyun Cui